GEN Exclusives

More »

Point of View

More »
May 15, 2010 (Vol. 30, No. 10)

The Ghosts of Medical Research

Promotional Marketing Haunts Studies Done on Behalf of Big Pharma's Drug Repertoire

  • Corporate Science

    In the ghost management of research and publication by drug companies we have a novel model of science. This is corporate science, done by many unseen workers, performed for marketing purposes, and drawing its authority from traditional academic science. The high commercial stakes mean that all of the parties connected with this new corporate science can find reasons or be induced to participate, support, and steadily normalize it. It also biases the available science by pushing favorable results and downplaying negative ones—and sometimes through outright fraud.

    As long as pharmaceutical companies hold the purse strings of medical research, medical knowledge will be selectively constructed, serving to market drugs, not to promote health. And as long as universities grovel for more partnerships with these companies, the door will remain wide open to proceed with the corruption of scientific research.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?